{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:20Z","timestamp":1792773380847,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a type of autoimmune encephalitis, and the common first symptoms are mental disorders, seizures, and rarely aphasia in patients. Meanwhile, movement disorders associated with anti-NMDAR encephalitis are usually chorea and dystonia, with peripheral nerve damage being rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We present a case of anti-NMDAR encephalitis with motor aphasia as the first symptom. The patient, a 16-year-old female, was admitted to the hospital with further progression of the disease, complicated by grand mal seizures with peripheral nerve damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Anti-NMDAR encephalitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient accepted first-line therapy, including methylprednisolone and intravenous immunoglobulin shock therapy, rituximab second-line treatment (rituximab), and third-line therapies (mycophenolate mofetil), as well as efgartigimod as an additional therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 6 weeks of comprehensive treatment, the patient\u2019s muscle strength in both lower limbs recovered, and the psychiatric symptoms and seizures improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case broadens the range of clinical symptoms of anti-NMDAR encephalitis, and we should recognize that motor aphasia may also be one of the first symptoms in adolescent patients with anti-NMDAR encephalitis. What\u2019s more, efgartigimod may be a promising treatment for patients with anti-NMDAR encephalitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042436","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T21:01:05Z","timestamp":1747083665000},"page":"e42436","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["An adolescent patient with anti-N-methyl-D-aspartate receptor encephalitis with motor aphasia as the first symptom and complicated by peripheral nerve damage: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-5661","authenticated-orcid":false,"given":"Lei","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan University of Science & Technology, Hanyang Hospital, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5453-6631","authenticated-orcid":false,"given":"Nao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2014.10.007","article-title":"Anti-NMDA receptor encephalitis, autoimmunity, and psychosis.","volume":"176","author":"Kayser","year":"2016","journal-title":"Schizophr Res"},{"key":"R2-20261023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2012.03.001","article-title":"Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology.","volume":"11","author":"Peery","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R3-20261023","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"R4-20261023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis.","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"key":"R5-20261023","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","article-title":"Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis.","volume":"70","author":"Kayser","year":"2013","journal-title":"JAMA Neurol"},{"key":"R6-20261023","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ene.12911","article-title":"Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China.","volume":"23","author":"Wang","year":"2016","journal-title":"Eur J Neurol"},{"key":"R7-20261023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13554794.2018.1524915","article-title":"Anti-NMDA receptor encephalitis presenting as isolated aphasia in an adult.","volume":"24","author":"Constantinides","year":"2018","journal-title":"Neurocase"},{"key":"R8-20261023","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejpn.2014.06.002","article-title":"Sudden and isolated Broca\u2019s aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children.","volume":"18","author":"Deiva","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"R9-20261023","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies.","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov Disord"},{"key":"R10-20261023","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.25354","article-title":"The spectrum of movement disorders in children with anti-NMDA receptor encephalitis.","volume":"28","author":"Baizabal-Carvallo","year":"2013","journal-title":"Mov Disord"},{"key":"R11-20261023","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/neuroindia.NI_739_16","article-title":"Movement disorders in anti-NMDA receptor encephalitis.","volume":"65","author":"Servais","year":"2017","journal-title":"Neurol India"},{"key":"R12-20261023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"R13-20261023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nic.2012.12.009","article-title":"Anti-NMDA receptor encephalitis.","volume":"23","author":"Jones","year":"2013","journal-title":"Neuroimaging Clin N Am"},{"key":"R14-20261023","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1007\/s10072-023-07018-x","article-title":"Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions.","volume":"44","author":"Bandeira","year":"2023","journal-title":"Neurol Sci"},{"key":"R15-20261023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"R16-20261023","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0333102414526070","article-title":"Anti-NMDAR encephalitis mimicking HaNDL syndrome.","volume":"34","author":"Finke","year":"2014","journal-title":"Cephalalgia"},{"key":"R17-20261023","doi-asserted-by":"crossref","first-page":"e13651","DOI":"10.1097\/MD.0000000000013651","article-title":"Anesthesia for patient with anti-N-methyl-D-aspartate receptor encephalitis: a case report with a brief review of the literature.","volume":"97","author":"Wada","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R18-20261023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pediatrneurol.2014.01.012","article-title":"Pediatric anti-NMDA (N-methyl D-aspartate) receptor encephalitis.","volume":"50","author":"Salvucci","year":"2014","journal-title":"Pediatr Neurol"},{"key":"R19-20261023","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/cjn.2017.280","article-title":"Adult-onset anti-N-methyl-D-aspartate-receptor encephalitis presenting as a non-fluent aphasia.","volume":"45","author":"Hebert","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"R20-20261023","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.2169\/internalmedicine.52.1065","article-title":"Ophthalmoplegia and flaccid paraplegia in a patient with anti-NMDA receptor encephalitis: a case report and literature review.","volume":"52","author":"Ishikawa","year":"2013","journal-title":"Intern Med"},{"key":"R21-20261023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000323751","article-title":"A young man with anti-NMDAR encephalitis following Guillain-Barre syndrome.","volume":"3","author":"Tojo","year":"2011","journal-title":"Case Rep Neurol"},{"key":"R22-20261023","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1002\/brb3.779","article-title":"Peripheral neuropathy in limbic encephalitis with anti-glutamate receptor antibodies: case report and systematic literature review.","volume":"7","author":"Wei","year":"2017","journal-title":"Brain Behav"},{"key":"R23-20261023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13054-023-04676-3","article-title":"Illness weakness, polyneuropathy and myopathy: diagnosis, treatment, and long-term outcomes.","volume":"27","author":"Latronico","year":"2023","journal-title":"Crit Care"},{"key":"R24-20261023","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1152\/japplphysiol.00019.2021","article-title":"Pathophysiology and management of critical illness polyneuropathy and myopathy.","volume":"130","author":"Cheung","year":"2021","journal-title":"J Appl Physiol (1985)"},{"key":"R25-20261023","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00134-020-05944-4","article-title":"ICU-acquired weakness.","volume":"46","author":"Vanhorebeek","year":"2020","journal-title":"Intensive Care Med"},{"key":"R26-20261023","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models.","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"R27-20261023","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R28-20261023","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1212\/NXI.0000000000001052","article-title":"International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis.","volume":"8","author":"Nosadini","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R29-20261023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jneuroim.2017.08.011","article-title":"Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.","volume":"312","author":"Sveinsson","year":"2017","journal-title":"J Neuroimmunol"},{"key":"R30-20261023","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval.","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"R31-20261023","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies.","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R32-20261023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:01:08Z","timestamp":1792767668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":32,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042436","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}